Prostate drugs warning issued in Canada

The prescription drugs finasteride, used to treat an enlarged prostate and male pattern baldness, and dutasteride, also to help men with the prostate condition, may increase the risk of high-grade prostate cancer, Health Canada warns.

The warning, issued Monday, comes following reviews of two international trials. However, it notes that high-grade prostate cancer, which grows and spreads more quickly than low-grade prostate cancer, is rare, and the increased risk of using the two drugs is still considered very small.

As a result of the assessment of the trials, new safety warnings have been added to the Canadian drug labels for finasteride and dutasteride products. Updates to labels for the generic forms of the two drugs are also coming.

Following are more details of the drugs:

Finasteride is available under the brand names Proscar (5 mg finasteride) and Propecia (1 mg finasteride), and their generic equivalents.

Dutasteride is available under the brand names Avodart and Jalyn (a combination drug product containing dutasteride and tamsulosin).

Proscar, Avodart and Jalyn treat benign prostatic hyperplasia (BPH), or an enlarged prostate, a common condition in men over 40. Propecia is used to treat male pattern hair loss.

Health Canada says its review of the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial which both sought to assess whether the two drugs were effective in preventing prostate cancer found men 50 and over who used 5 mg of finasteride and dutasteride over four years had a "small but statistically significant increased risk of high-grade prostate cancer."

The federal department noted that the 1 mg finasteride strength (Propecia) was not included in these trials, "but a potential risk has not been ruled out."

Finasteride and dustasteride are not approved for the prevention of prostate cancer in Canada.

See the article here:
Prostate drugs warning issued in Canada